Atossa Therapeutics Newsroom

Atossa Therapeutics to Present Poster on (Z)-Endoxifen at AACR Special Conference in Cancer Research

GlobeNewswireNov 21 21:30

Atossa Therapeutics To Present Five Abstracts For Data Regarding (Z)-Endoxifen At 2024 San Antonio Breast Cancer Symposium

BenzingaNov 20 21:31

Express News | Atossa Therapeutics- Got Into Open Market Sale Agreement, May Offer & Sell Shares of Our Common Stock of up to $100 Mln From Time to Time - SEC Filing

BreakingsNov 20 05:32

H.C. Wainwright Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Raises Target Price to $7

Futu NewsNov 13 19:31 · Ratings

Promising Developments in Atossa Therapeutics: Advancing Endoxifen Treatments

TipRanksNov 13 19:26

Atossa Therapeutics | 8-K: Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

SECNov 13 01:18

Atossa Therapeutics | 10-Q: Q3 2024 Earnings Report

SECNov 13 01:18 · Announcements

Atossa Therapeutics GAAP EPS of -$0.06 In-line

Seeking AlphaNov 12 21:36

Express News | Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

BreakingsNov 12 21:30

Express News | Atossa Therapeutics Q3 Operating Expenses USD 6.385 Million

BreakingsNov 12 21:30

Press Release: Atossa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Dow JonesNov 12 21:30

Atossa Therapeutics 3Q Loss/Shr 6c >ATOS

Dow JonesNov 12 21:30

Press Release: Atossa Therapeutics Appoints Claudia Lopez, DVM, MSc, as Vice President, Clinical Product Development

Dow JonesNov 5 21:30

Express News | Atossa Therapeutics Appoints Claudia Lopez, Dvm, MSC, as Vice President, Clinical Product Development

BreakingsNov 5 21:30

Promising Phase 2 Results and Strong Safety Profile Support Buy Recommendation for Atossa Therapeutics

TipRanksNov 4 22:45

Atossa Therapeutics Reports Phase 2 Data for Breast Cancer Prevention

BenzingaNov 4 19:33

Atossa Therapeutics Reports Positive KARISMA-Endoxifen Trial Results:

GlobeNewswireNov 4 19:30

Maxim Group Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $4

Futu NewsNov 2 03:31 · Ratings

H.C. Wainwright Maintains Atossa Therapeutics(ATOS.US) With Buy Rating, Maintains Target Price $6

Futu NewsOct 31 22:31 · Ratings

Express News | Atossa - (Z)-Endoxifen at 10 Mg Once Daily Met Primary Endpoint With 19/20 (95%) Receiving > 75 % of Planned Treatment in I-Spy-2 Phase 2 Trial

BreakingsOct 31 20:15